Pulmonary arterial hypertension (PAH) in connective tissue diseases

Rheumatology

Volumn 45, Issue SUPPL. 3, 2006, Pages

  Kähler, Christian M ^a   Colleselli, D ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; SITAXSENTAN; UNIPROST;

ANGIOGENESIS; ARTERY THROMBOSIS; BLOOD VESSEL WALL; CAUSE OF DEATH; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; EPIDEMIOLOGICAL DATA; HEART LEFT RIGHT SHUNT; HEART RIGHT VENTRICLE FAILURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IDIOPATHIC DISEASE; INFLAMMATION; LUNG ARTERY PRESSURE; LUNG BLOOD VESSEL; LUNG TRANSPLANTATION; LUNG VASCULAR RESISTANCE; PATHOGENESIS; PORTAL HYPERTENSION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; TREATMENT PLANNING; VASOMOTOR DISORDER;

CONNECTIVE TISSUE DISEASES; HUMANS; HYPERTENSION, PULMONARY;

EID: 33748993677     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kel291     Document Type: Review

References (21)

1. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351:1425-36.
2. Galie N, Manes A, Farahani KV et al. Pulmonary arterial hypertension associated to connective tissue diseases. Lupus 2005;14:713-7.
3. Yoshida S, Katayama M. Pulmonary hypertension in patients with connective tissue diseases. Nippon Rinsho 2001;59:1164-7.
4. Rich S, Dantzker DR, Ayres SM et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987;107:216-23.
5. Humbert M, Simonneau G. Drug Insight: Endothelin-receptor antagonists for pulmonary arterial hypertension in systemic rheumatic diseases. Nat Clin Pract 2005;1:93-101.
6. Mukerjee D, St George D, Coleiro B et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003;62:1088-93.
7. MacGregor AJ, Canavan R, Knight C et al. Pulmonary hypertension in systemic sclerosis: Risk factors for progression and consequences for survival. Rheumatology 2001;40:453-9.
8. Humbert M, Chaouat A, Bertocchi M et al. ItinerAIR-HTAP: A French National Prospective Registry of Pulmonary Arterial Hypertension. Am J Respir Crit Care Med 2004;169:A169.
9. Haas C. Pulmonary hypertension associated with systemic lupus erythematosus. Bull Acad Natl Med 2004;188:985-97.
10. Pietra GG, Capron F, Stewart S et al. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol 2004;43:25-32.
11. Budhiraja R, Tuder RM, Hassoun PM. Endothelial dysfunction in pulmonary hypertension. Circulation 2004;109:159-65.
12. Barst RJ, McGoon M, Torbicki A et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:40-7.
13. Murata I, Kihara H, Shinohara S, Ito K. Echocardiographic evaluation of pulmonary arterial hypertension in patients with progressive systemic sclerosis and related syndromes. Jpn Circ J 2006;173:744-750.
14. Leuchte HH, Baumgartner RA, El Nounou M et al. Brain natriuretic peptide is a prognostic parameter in chronic lung disease. Am J Respir Crit Care Med 2006.
15. Badesch DB, Tapson VF, McGoon MD et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000;132:425-34.
16. Humbert M, Sanchez O, Fartoukh M et al. Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: Results of a pilot study. Eur Respir J 1999;13:1351-6.
17. Oudiz RJ, Schilz RJ, Barst RJ et al. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest 2004;126:420-7.
18. Rubin LJ, Badesch DB, Barst RJ et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.
19. Denton CP. Dual endothelin receptor antagonism in pulmonary arterial hypertension related to systemic sclerosis. Eur J Clin Invest 2005;35:AI72.
20. Barst RJ, Langleben D, Frost A et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004;169:441-7.
21. Galie N, Ghofrani HA, Torbicki A et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148-57.